The Oncotype DX Breast Recurrence^® test provides significant value in clinical practice

For node-positive, early-stage breast cancer patients

The Oncotype DX Breast Recurrence Score test is predictive of chemotherapy benefit for your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by SWOG-8814¹. Data from SWOG-8814 and RxPONDER show that a substantial proportion of these patients may be spared chemotherapy^1-3.

Postmenopausal vs Premenopausal graphic

HOW DOES THE ONCOTYPE DX TEST HELP GUIDE TREATMENT DECISIONS?
SWOG 8814 study established the Oncotype DX^® test as predictive of CT benefit in node-positive postmenopausal patients¹. Initial results from the RxPONDER study add to the findings of SWOG 8814 by providing a refined estimate of CT benefit in N1 patients with the following results^2,3:

N1 postmenopausal patients with Recurrence Score^® results 0-25 may be spared chemotherapy, independent of clinical pathological parameters^2,3.

N1 premenopausal patients with Recurrence Score results 0-25 derive a 2.4% benefit from chemotherapy in terms of distant recurrence-free interval at 5 years³.

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy^1-3

A large proportion^4,5 of HR+, HER2-, node-positive postmenopausal patients receive chemotherapy as node-positive disease is considered high clinical risk due to worse prognosis⁶. Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population^4,5. RxPONDER demonstrated that many of these patients may be overtreated, assuming that chemotherapy was considered because of their high clinical risk^2,3, and the Oncotype DX test can help make informed treatment decisions.

Another recent study published in 2023 shows that the Oncotype DX test increases confidence and concordance among oncologists in adjuvant chemotherapy recommendations for early-stage breast cancer⁸

The study concludes that

the Oncotype DX^® test significantly reduces uncertainty related to therapeutic decisions
the Oncotype DX^® test reduces discordance in treatment choice among oncologists

READ THE PAPER ON NPJ | Breast Cancer

CLINICAL UTILITY OF THE ONCOTYPE DX TEST

In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify a significant proportion of node-positive patients (with up to 3 positive nodes) who may not benefit from the addition of chemotherapy^1-3.

The Oncotype DX Breast Recurrence Score^* test should be used for:

All patients for whom chemotherapy may be spared^1-3
All patients for whom chemotherapy may be life-saving^1-3

*For early stage, HR+, HER2- patients with up to 3 nodes involved

REFERENCES
Albain et al. Lancet Oncol. 2010.

Kalinsky et al. NEJM. 2021.

Kalinsky et al. SABCS. 2021.

Allemani et al. Int J Cancer. 2013.

Zhang et al. Breast Can Res Treat. 2020.

Tonellotto et al. Eur J Breast Health. 2019.

Bello et al. Ann Surg One. 2018.

Licata L, et al. NPJ Breast Cancer. 2023.

Contact Us

GET IN TOUCH

Case study library

The Oncotype DX Breast Recurrence® test provides significant value in clinical practice

Share

For node-positive, early-stage breast cancer patients

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy1-3

CLINICAL UTILITY OF THE ONCOTYPE DX TEST

*For early stage, HR+, HER2- patients with up to 3 nodes involved

Improved confidence and agreement in adjuvant chemotherapy decisions

Do You Have a Question?

Contact Us

The Oncotype DX Breast Recurrence^® test provides significant value in clinical practice

Use of the Oncotype DX test may reduce the risk of overtreatment with chemotherapy^1-3